ALK has announced that its EURneffy 1mg nasal adrenaline spray has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for ...
An adrenaline nasal spray for the emergency treatment of anaphylaxis has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA). This marks the first time a needle-free ...
EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma’s partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the ...
The European Medicines Agency has recommended the first emergency treatment for allergic reactions to be administered as a nasal spray, not as an injection. Eurneffy (epinephrine) should be granted a ...
The positive CHMP opinion supports an extension to the existing marketing authorisation for EUR neffy® 2 mg granted by the European Commission (‘EC’) in August 2024 for the emergency treatment of ...
EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results